FENM and Acetylcholinesterase Inhibitor Combination at Lower Doses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, particularly Alzheimer's disease, lack efficacy in early stages and are associated with significant adverse effects, limiting their long-term use, and there is a need for more effective therapies that can slow disease progression.
Innovation Solution
A synergistic combination of 3-(2-fluoroethyl)adamantan-1-amine (FENM) with at least one acetylcholinesterase inhibitor, such as donepezil, galantamine, or rivastigmine, administered at reduced doses to enhance cognitive preservation and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single agent is used to treat Alzheimer's disease, then the treatment is simple, but the efficacy is insufficient
Solution Approach 1:
The patent combines fenobam (a metabotropic glutamate receptor modulator) with an acetylcholinesterase inhibitor into a single pharmaceutical composition, merging two different mechanisms of action into one treatment regimen to achieve synergistic cognitive enhancement while simplifying administration compared to separate therapies
2Reliability
If multiple agents are combined to improve treatment efficacy, then the cognitive enhancement is synergistic, but the side effects increase
Solution Approach 1:
The patent optimizes the dosage parameters of fenobam (0.5-5 mg/kg/day) and acetylcholinesterase inhibitor (0.1-10 mg/kg/day) to achieve synergistic cognitive enhancement while minimizing side effects, demonstrating that proper parameter selection can resolve the contradiction between efficacy and safety
3Reliability
If high doses of a single agent are used to achieve therapeutic effect, then the cognitive improvement is sufficient, but the adverse reactions increase
Solution Approach 1:
The patent distributes the therapeutic effect across two agents at lower individual doses, where fenobam and acetylcholinesterase inhibitor work synergistically to achieve the desired cognitive improvement without the adverse reactions associated with high-dose monotherapy
Data Source
Figure 1A~1B
Figure 2A~2B
AI summary
The invention relates to a composition comprising a synergistic combination of fluoroethylnormemantine (FENM) and of at least one acetylcholinesterase inhibitor. More particularly, the invention relates to said composition for use thereof as a medicament, even more particularly for use thereof in the treatment of a pathological condition selected from tauopathies, synucleinopathies, amyloidopathies, Alzheimer's disease, Parkinson's disease, multiple system atrophy, Huntington's disease, posterior cortical atrophy, Pick's disease, epilepsy, vascular dementia, frontotemporal dementia, Lewy body dementia and amyotrophic lateral sclerosis.